JP2021505661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505661A5 JP2021505661A5 JP2020548883A JP2020548883A JP2021505661A5 JP 2021505661 A5 JP2021505661 A5 JP 2021505661A5 JP 2020548883 A JP2020548883 A JP 2020548883A JP 2020548883 A JP2020548883 A JP 2020548883A JP 2021505661 A5 JP2021505661 A5 JP 2021505661A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- composition according
- complex
- asparaginase
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024023383A JP2024069234A (ja) | 2017-11-30 | 2024-02-20 | アスパラギナーゼを用いた治療法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592982P | 2017-11-30 | 2017-11-30 | |
| US62/592,982 | 2017-11-30 | ||
| US201862625078P | 2018-02-01 | 2018-02-01 | |
| US62/625,078 | 2018-02-01 | ||
| US201862631142P | 2018-02-15 | 2018-02-15 | |
| US62/631,142 | 2018-02-15 | ||
| US201862673075P | 2018-05-17 | 2018-05-17 | |
| US62/673,075 | 2018-05-17 | ||
| PCT/US2018/063448 WO2019109018A1 (en) | 2017-11-30 | 2018-11-30 | Methods of treatment with asparaginase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024023383A Division JP2024069234A (ja) | 2017-11-30 | 2024-02-20 | アスパラギナーゼを用いた治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505661A JP2021505661A (ja) | 2021-02-18 |
| JP2021505661A5 true JP2021505661A5 (enExample) | 2022-01-04 |
Family
ID=66664263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548883A Pending JP2021505661A (ja) | 2017-11-30 | 2018-11-30 | アスパラギナーゼを用いた治療法 |
| JP2024023383A Pending JP2024069234A (ja) | 2017-11-30 | 2024-02-20 | アスパラギナーゼを用いた治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024023383A Pending JP2024069234A (ja) | 2017-11-30 | 2024-02-20 | アスパラギナーゼを用いた治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230173042A1 (enExample) |
| EP (1) | EP3716997A4 (enExample) |
| JP (2) | JP2021505661A (enExample) |
| KR (2) | KR20200119234A (enExample) |
| CN (1) | CN111818937A (enExample) |
| AU (2) | AU2018375183B2 (enExample) |
| BR (1) | BR112020010976A2 (enExample) |
| CA (2) | CA3083499C (enExample) |
| IL (1) | IL274865B2 (enExample) |
| MX (1) | MX2020005567A (enExample) |
| SG (1) | SG11202004965RA (enExample) |
| WO (1) | WO2019109018A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
| US20220313798A1 (en) * | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| EP4319818A1 (en) * | 2021-04-06 | 2024-02-14 | Jazz Pharmaceuticals Ireland Ltd. | Formulations of l-asparaginase |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US20260007728A1 (en) | 2022-07-14 | 2026-01-08 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1337630A2 (en) * | 2000-11-28 | 2003-08-27 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| CN1360049A (zh) * | 2000-12-20 | 2002-07-24 | 上海博德基因开发有限公司 | 一种新的多肽——人l－天冬酰胺酶24.53和编码这种多肽的多核苷酸 |
| US7985548B2 (en) * | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| ITMI20060612A1 (it) * | 2006-03-30 | 2007-09-30 | Keryos Spa | New activaded poly-ethylene glycols-and related polymers and their applications |
| WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| US20150086521A1 (en) * | 2012-03-21 | 2015-03-26 | Erytech Pharma | Medicament for the Treatment of Acute Myeloid Leukemia (AML) |
| CN105802946B (zh) * | 2014-12-29 | 2025-08-22 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化的门冬酰胺酶及其应用 |
| CN105802948B (zh) * | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
| US11504418B2 (en) * | 2016-11-04 | 2022-11-22 | Crowpierce Technologies, Llc | Endotoxin free asparaginase |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2018
- 2018-11-30 AU AU2018375183A patent/AU2018375183B2/en active Active
- 2018-11-30 EP EP18884437.7A patent/EP3716997A4/en active Pending
- 2018-11-30 CA CA3083499A patent/CA3083499C/en active Active
- 2018-11-30 MX MX2020005567A patent/MX2020005567A/es unknown
- 2018-11-30 KR KR1020207018920A patent/KR20200119234A/ko not_active Ceased
- 2018-11-30 KR KR1020257018693A patent/KR20250086810A/ko active Pending
- 2018-11-30 WO PCT/US2018/063448 patent/WO2019109018A1/en not_active Ceased
- 2018-11-30 JP JP2020548883A patent/JP2021505661A/ja active Pending
- 2018-11-30 CN CN201880084869.5A patent/CN111818937A/zh active Pending
- 2018-11-30 CA CA3240356A patent/CA3240356A1/en active Pending
- 2018-11-30 US US16/767,920 patent/US20230173042A1/en active Pending
- 2018-11-30 IL IL274865A patent/IL274865B2/en unknown
- 2018-11-30 SG SG11202004965RA patent/SG11202004965RA/en unknown
- 2018-11-30 BR BR112020010976-2A patent/BR112020010976A2/pt unknown
-
2024
- 2024-02-20 JP JP2024023383A patent/JP2024069234A/ja active Pending
- 2024-12-11 AU AU2024278286A patent/AU2024278286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505661A5 (enExample) | ||
| JP2024069234A5 (enExample) | ||
| Pasut et al. | PEG conjugates in clinical development or use as anticancer agents: an overview | |
| Hughes et al. | T‐cell modulation by cyclophosphamide for tumour therapy | |
| AU2005314468B2 (en) | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases | |
| JP2012532185A5 (enExample) | ||
| Koga et al. | Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts | |
| KR101705077B1 (ko) | Ｈｐｍａ-도세탁셀 또는 젬시타빈 컨쥬게이트 및 이의 용도 | |
| US10428114B2 (en) | Type polypeptide targeting tumours | |
| FI2451486T4 (fi) | Pegyloitu L-asparaginaasi | |
| WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
| Rueda et al. | Targeting the chemokine receptor CXCR4 for cancer therapies | |
| US10632081B2 (en) | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | |
| Singh et al. | Polymer drug conjugates: recent advancements in various diseases | |
| JP2023548310A (ja) | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート | |
| JP2021001184A (ja) | ペグ化インターフェロンのための投薬計画 | |
| Qin et al. | CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies | |
| Vine et al. | Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery: Vine et al. | |
| JP2018530525A5 (enExample) | ||
| KR101560339B1 (ko) | 의약 조성물 또는 조합제 | |
| Stafylidis et al. | Novel perspectives on thrombopoietin receptor agonists applications | |
| Russell-Jones et al. | Increasing the tumoricidal activity of daunomycin-pHPMA conjugates using vitamin B12 as a targeting agent | |
| CN112915101A (zh) | 一种抗肿瘤联合药物组合物及其应用 | |
| JP2015500836A5 (enExample) | ||
| Chang et al. | Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer |